trial · primary record
Lymphodepleting chemotherapy: Cyclophosphamide
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 32 |
| Primary completion | 2033-08-31 |
| Primary endpoint | Incidence of Dose-Limiting Toxicities (DLTs) |
| Registry ID | NCT07725406 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:49.879Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07725406
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.